drugset
drugset / Trial / NCT01943721

A Study of the VISION5 Product in Patients With Glaucoma or Ocular Hypertension

NCT01943721 ↗

Phase 1 Completed 14 enrolled ForSight Vision5, Inc.
NaSingle-groupOpen-labelPrevention

Summary

The objective of this Phase 1 study is to evaluate the VISION5 Product's safety and efficacy.

Timeline

Start
2013-10
Primary completion
2014-06
Completion
2014-06

Drugs

EvaluationDrugModalityDoseRoute
Subject VISION5 Product Unknown — —

Indications

ocular hypertension open-angle glaucoma